leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   99 Trials   99 Trials   2505 News 


12345678910111213...3839»
  • ||||||||||  Network-based discovery of tumor-checkpoint inverter drugs targeting pancreatic ductal adenocarcinoma cell states and macrophage reprogramming (Section 16) -  Mar 17, 2026 - Abstract #AACR2026AACR_5807;    
    Predicted MR-inversion scores correlated with experimental dose-response profiles in cell lines selected via OncoMatch.Together, these results establish a mechanistic link between tumor-intrinsic transcriptional states and macrophage immunosuppression, while identifying mutation-agnostic, state-specific drugs capable of reprogramming both tumor and immune compartments. This work provides a generalizable framework for network-based drug repurposing to overcome transcriptional plasticity and immune resistance in PDAC.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., leuprolide acetate injection / Generic mfg.
    Journal:  Sterile abscess following intramuscular leuprolide acetate injection for endometriosis: A case report. (Pubmed Central) -  Mar 13, 2026   
    LA is a common treatment for refractory endometriosis in pediatric patients, but providers may be unaware of the risk of sterile abscess. We did not identify any predictive or preventative factors but propose that prior treatment may have increased risk in this case.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
    Initial experience with bicalutamide and leuprorelin acetate combination therapy for AR-positive salivary duct carcinoma (Poster Room | Pacifico Yokohama Exhibition Hall D) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_1407;    
    Even patients with comorbidities such as chronic obstructive pulmonary disease (COPD) and cerebellar infarction achieved PR and were able to continue treatment. [Conclusions] This study suggests that CAB therapy in elderly patients with comorbidities such as COPD who are not candidates for cytotoxic anticancer drug treatment may be able to continue treatment effectively.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., abiraterone acetate / Generic mfg., bicalutamide / Generic mfg.
    Target Hormonal Pathway: Androgen Deprivation Therapy for Patients with AR-Positive Metastatic Salivary Gland Carcinoma (Poster Room | Pacifico Yokohama Exhibition Hall D) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_1394;    
    [Conclusions] Metastatic salivary gland carcinoma is associated with a poor prognosis making the exploration of new treatment options essential. Previous studies have suggested potential benefits of androgen deprivation therapy; however further research is needed to fully evaluate its efficacy and establish the role in management.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
    Favorable Response to Androgen Deprivation in a Lung Salivary Gland-Type Tumor with Low Androgen Receptor Expression (Poster Room | Pacifico Yokohama Exhibition Hall D) -  Mar 2, 2026 - Abstract #JSMO2026JSMO_1386;    
    With the use of ADT, most studies report response if AR positivity is more than 30%. This case provides evidence that ADT may offer clinical benefit in tumors with low AR expression, and its use should be considered when other systemic options are inaccessible or contraindicated.
  • ||||||||||  Preclinical, Journal:  Combination Hormonal Drug Therapy Inhibits In (Pubmed Central) -  Feb 20, 2026   
    MHC I activity and DNA damage response were upregulated. This anti-hormonal drug regimen for AGCT merits prospective investigation.
  • ||||||||||  Journal:  Dydrogesterone and Letrozole Combination for the Treatment of Endometriosis: A Mechanism-Based Therapeutic Approach. (Pubmed Central) -  Feb 16, 2026   
    Based on existing literature, dydrogesterone is thought to counteract estrogen-driven endometrial proliferation through progesterone receptor activation, while letrozole is believed to reduce estrogen biosynthesis by inhibiting aromatase, which may collectively influence lesion growth and inflammatory processes. Additional long-term studies are warranted to thoroughly assess the safety profile, clinical effectiveness, and overall therapeutic relevance of the dydrogesterone-letrozole combination for the treatment of endometriosis.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Biomarker, Journal:  A single biomarker may not yield a reliable binary clinical answer: B cell lymphoma 6 testing and resulting interventions for endometriosis in infertility care. (Pubmed Central) -  Feb 16, 2026   
    Of the patients treated for their positive BCL6 results, 20 (86%) were treated with leuprolide acetate, 9 (39%) with an aromatase inhibitor, and 1 (4%) was surgically managed with a laparoscopy in preparation for their frozen embryo transfer...The relationship between BCL6 and endometriosis may not be the golden solution to a single marker focus for testing, or for subsequent therapy planning among infertility patients. Clinicians should be cautious in using single marker testing for diagnosing and treating endometriosis in patients without strong additional therapeutic evidence.
  • ||||||||||  Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
    Trial completion date:  REVELUTION: RElugolix VErsus LeUprolide Cardiac Trial (clinicaltrials.gov) -  Feb 13, 2026   
    P2,  N=94, Active, not recruiting, 
    Clinicians should be cautious in using single marker testing for diagnosing and treating endometriosis in patients without strong additional therapeutic evidence. Trial completion date: Dec 2025 --> Oct 2026
  • ||||||||||  Review, Journal, HEOR, Real-world evidence:  Challenges in analyzing real-world evidence: analysis of androgen deprivation therapy use for prostate cancer in the REASSURE study. (Pubmed Central) -  Feb 6, 2026   
    While some patterns of ADT use in REASSURE were consistent with recommendations from clinical practice guidelines, there were also some inconsistencies. Findings from REASSURE highlighted the importance of considering potential differences in health care systems, population coverage, and patient data collection between regions, as well as incorporating data from multiple sources to capture data from more diverse patient populations, thus improving the quality of outputs from real-world studies.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Trial completion date:  Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov) -  Jan 23, 2026   
    P2,  N=60, Active, not recruiting, 
    These findings support incorporating a short neoadjuvant "window" before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs. antagonist trajectories. Trial completion date: Dec 2025 --> Jun 2026
  • ||||||||||  medroxyprogesterone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
    Preclinical, Journal:  Progestin-suppressed in vitro fertilization cycles yield similar outcomes to traditional protocols in patients with diminished ovarian reserve. (Pubmed Central) -  Dec 31, 2025   
    In multivariable models, the treatment group was not associated with the likelihood of having an embryo available for transfer (odds ratio 1.26, 95% confidence interval 0.74-1.53) or clinical pregnancy (odds ratio 0.98, 95% confidence interval 0.50-1.95). The progestin-suppressed IVF protocol provides similar reproductive outcomes in patients with diminished ovarian reserve, with the advantages of fewer monitoring visits, reduced injections, and lower medication costs.
  • ||||||||||  sunitinib / Generic mfg.
    Trial completion date, Trial primary completion date:  Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) -  Dec 26, 2025   
    P2,  N=64, Active, not recruiting, 
    The progestin-suppressed IVF protocol provides similar reproductive outcomes in patients with diminished ovarian reserve, with the advantages of fewer monitoring visits, reduced injections, and lower medication costs. Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Journal:  Late-stage Tyrosine ortho-C(sp2)-H Alkenylation for Macrocyclic Peptide SuFEx Proximity Labeling and Targeted Degradation. (Pubmed Central) -  Dec 26, 2025   
    We further developed a covalent cyclic peptide-lysosome targeting chimera (CCP-TAC) that selectively degrades PD-L1, remodels the tumor immune microenvironment, and exhibits favorable biosafety in vivo. Together, these findings establish tyrosine-directed C?H functionalization as a versatile platform for multifunctional cyclic peptides, bridging synthetic methodology with therapeutic application and advancing peptide stapling, covalent labeling, and degrader technologies.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
    Journal:  Cerebellar Hemangioblastoma Resection Complicated by Postoperative Vasogenic Edema in the Setting of Concurrent Immunotherapy Treatment. (Pubmed Central) -  Dec 24, 2025   
    Our patient's postoperative edema was successfully managed via decompressive laminectomy and placement of a ventriculoperitoneal shunt, with resolution of symptoms seen postoperatively and at the 12-week follow-up. Tumor surgeons should be advised that patients on chemotherapy and immunotherapy agents may be at higher risk of postoperative edema and an associated mass effect on the surrounding structures.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Journal:  Impact of sleep fragmentation and estradiol suppression on positive and negative affect: Results of an experimental model of menopause. (Pubmed Central) -  Dec 21, 2025   
    Our findings show that MT-related characteristics significantly disrupt both positive and negative affect, potentially underlying emergence of depressive symptoms during this reproductive stage. We observed differential effects on positive and negative affect, with sleep fragmentation having a greater effect on NA and estradiol and VMS having a greater effect on PA, suggesting benefit for tailoring interventions that target specific types of affect regulation.
  • ||||||||||  Journal:  Unresectable Desmoplastic Small Round Cell Tumor: A Case Report and Review of the Literature. (Pubmed Central) -  Dec 5, 2025   
    In patients with androgen receptor positivity, hormonal blockade with leuprolide and bicalutamide may be a therapeutic option, particularly in frail patients...DSRCT is a challenging and aggressive malignancy requiring a multidisciplinary and individualized approach. The combination of systemic therapy and local control measures remains critical for improving patient outcomes.